| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | Dec 15, 2025 | Wave Life Sciences Ltd. | 10% Owner | Buy | 97.5 | +1,470,000 | 8.76% | ✗ | $27.9M |
| Sep 27, 2024 | Oct 1, 2024 | Wave Life Sciences Ltd. | 10% Owner | Buy | 100.0 | +2,791,930 | 19.97% | ✗ | $22.3M |
| Dec 7, 2023 | Jan 30, 2024 | GSK plc | 10% Owner | Buy | 100.0 | +3,300,000 | 30.89% | ✗ | $16.5M |
| Sep 16, 2022 | Sep 20, 2022 | GSK plc | Other | Sell | 15.0 | -9,644,807 | -100.00% | ✗ | $94M |
| Jul 2, 2021 | Jul 6, 2021 | GSK plc | 10% Owner | Buy | 100.0 | +275,000 | 37.54% | ✗ | $5M |
| May 20, 2021 | May 24, 2021 | GSK plc | 10% Owner | Sell | 15.0 | -32,005,260 | -100.00% | ✗ | $392.1M |
| Feb 17, 2021 | Feb 19, 2021 | GSK plc | Director | Buy | 100.0 | +150,000 | 14.51% | ✗ | $2.7M |
| Jul 14, 2020 | Sep 18, 2020 | BICYCLE THERAPEUTICS PLC | 10% Owner | Sell | 40.0 | -4,744 | -0.25% | ✗ | $91.8K |
| Jul 14, 2020 | Jul 16, 2020 | Nkarta, Inc. | Director | Buy | 100.0 | +833,333 | 35.96% | ✗ | $15M |
| May 20, 2020 | May 21, 2020 | Progyny, Inc. | 10% Owner | Sell | 15.0 | -4,000,000 | -39.07% | ✗ | $103M |
| May 28, 2019 | May 30, 2019 | BICYCLE THERAPEUTICS PLC | Director | Buy | 100.0 | +385,714 | 25.22% | ✗ | $5.4M |
| Jul 17, 2018 | Jul 17, 2018 | Spero Therapeutics, Inc. | 10% Owner | Buy | 92.5 | +80,000 | 4.31% | ✗ | $1M |
| Nov 6, 2017 | Nov 7, 2017 | Spero Therapeutics, Inc. | 10% Owner | Buy | 100.0 | +428,571 | 30.07% | ✗ | $6M |
| Oct 24, 2016 | Oct 26, 2016 | CRISPR Therapeutics AG | 10% Owner | Buy | 85.0 | +66,500 | 2.11% | ✗ | $931K |
| Mar 14, 2016 | Mar 15, 2016 | Theravance Biopharma, Inc. | 10% Owner | Buy | 100.0 | +1,301,015 | 15.59% | ✗ | $30T |
| Oct 7, 2015 | Oct 7, 2015 | Theravance Biopharma, Inc. | 10% Owner | Buy | 80.0 | +44,574 | 0.54% | ✗ | $27.1B |
| Aug 7, 2015 | Aug 7, 2015 | Innoviva, Inc. | 10% Owner | Buy | 80.0 | +245,828 | 0.77% | ✗ | $856.9B |
| May 11, 2015 | May 11, 2015 | Innoviva, Inc. | 10% Owner | Buy | 72.5 | +85,579 | 0.27% | ✗ | $117.2B |
| Mar 2, 2015 | Mar 2, 2015 | Innoviva, Inc. | 10% Owner | Buy | 72.5 | +92,674 | 0.29% | ✗ | $155.1B |
| Nov 4, 2014 | Nov 4, 2014 | Innoviva, Inc. | 10% Owner | Buy | 95.0 | +832,456 | 2.71% | ✗ | $10.6T |
| Aug 11, 2014 | Aug 11, 2014 | Innoviva, Inc. | 10% Owner | Buy | 80.0 | +172,651 | 0.56% | ✗ | $675.5B |
| May 9, 2014 | May 13, 2014 | Innoviva, Inc. | 10% Owner | Buy | 90.0 | +317,770 | 1.05% | ✗ | $2.7T |
| Feb 11, 2014 | Feb 13, 2014 | Innoviva, Inc. | 10% Owner | Buy | 90.0 | +342,229 | 1.14% | ✗ | $4.4T |
| Oct 29, 2013 | Oct 29, 2013 | Innoviva, Inc. | 10% Owner | Buy | 72.5 | +130,473 | 0.44% | ✗ | $641.1B |
| Jul 30, 2013 | Aug 1, 2013 | Innoviva, Inc. | 10% Owner | Buy | 100.0 | +3,064,407 | 11.47% | ✗ | $342.8T |
| Apr 30, 2013 | Apr 30, 2013 | Innoviva, Inc. | 10% Owner | Buy | 80.0 | +193,563 | 0.73% | ✗ | $1.3T |
| Feb 15, 2013 | Feb 20, 2013 | Innoviva, Inc. | 10% Owner | Buy | 72.5 | +116,527 | 0.44% | ✗ | $299.1B |
| Nov 2, 2012 | Nov 5, 2012 | Innoviva, Inc. | 10% Owner | Buy | 90.0 | +280,348 | 1.07% | ✗ | $1.8T |
| Aug 3, 2012 | Aug 7, 2012 | Innoviva, Inc. | 10% Owner | Buy | 88.8 | +316,334 | 1.23% | ✗ | $8.9M |